Cytokinetics, Inc.

Smithkline Beecham Corporation

Casi Pharmaceuticals, Inc.

Bing Yao

David John Morgans, Jr

Bradley Paul Morgan

Xiangping Qian

Gustave Bergnes

Steven David Knight

Dashyant Dhanak

Han-Jie Zhou

Luke W Ashcraft

Kevin J Duffy

Nicholas D Adams

Cynthia A Parrish

Jianchao Wang

Duke Fitch

Rosanna Tedesco

Pu-Ping Lu

Andrew I McDonald

Jennifer Kuo Chen Huang

Chihyuan (Grace) Chuang

Wenyue Wang

Qing (Kevin) Lu

Whitney Walter Smith

Andrew MacDonald

Described herein are crystalline forms of 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, and pharmaceutically acceptable salts and solvates thereof. Also described herein are pharmaceutical formulations of 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, and pharmaceutically acceptable salts and solvates thereof.

Crystalline forms and formulations of a VCP/p97 inhibitor

Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.

Certain chemical entities, compositions, and methods

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.

Imidazole-benzamide anti-cancer agents

Imidazopyridinyl benzamide mitotic kinesin inhibitors

Provided are compounds of Formula V and pharmaceutically acceptable salts thereof which may be useful for the treatment of cancer or other proliferative disorders. 

Imidazoyl-benzamide anti-cancer agents

Imidazopyridinyl-benzamide anti-cancer agents

Provided are compounds of Formula I and pharmaceutically acceptable salts thereof which may be useful for the treatment of cancer or other proliferative disorders. 

A method of modulating KSP kinesin activity in vitro comprising contacting KSP kinesin with at least one chemical entity chosen from compounds represented by Formula I: and pharmaceutically acceptable salts thereof, where the variables are as defined further herein.

Modulation of KSP kinesin activity with heterocyclic-fused pyrimidinone derivatives

Compounds, compositions and methods useful for treating cellular proliferative diseases and disorders, for example, by modulating the activity of KSP, are disclosed.

Compounds, compositions, and methods

Provided herein are certain compounds of Formula I:that can be used to treat diseases of proliferating cells. The compounds are KSP kinesin inhibitors, particularly inhibitors of human KSP.

3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use

Racemates are obtained from one of the enantiomers, or an enantiomerically enriched mixture, of an optically active quinazolinone derivative by reaction of the compound with an alkali alkoxide of a primary alcohol and isolation of the racemate.

Process for the racemization of chiral quinazolinones

Growing community of inventors

Millbrae, CA, United States of America

Bing Yao